Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Headache ; 55(2): 301-9, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25598270

RESUMEN

BACKGROUND: Migraine is a highly disabling disease affecting a significant proportion of the Australian population. The methylenetetrahydrofolate reductase (MTHFR) C677T variant has been associated with increased levels of homocysteine and risk of migraine with aura (MA). Folic acid (FA), vitamin B6 , and B12 supplementation has been previously shown to reduce increased levels of homocysteine and decrease migraine symptoms. However, the influence of dietary folate intake on migraine has been unclear. The aim of the current study was to analyze the association of dietary folate intake in the form of dietary folate equivalent, FA, and total food folate (TFF) on migraine frequency, severity, and disability. METHODS: A cohort of 141 adult females of Caucasian descent with MA was genotyped for the MTHFR C677T variant using restriction enzyme digestion. Dietary folate information was collected from all participants and analyzed using the "FoodWorks" 2009 package. Folate consumption was compared with migraine frequency, severity, and disability using linear regression. RESULTS: A significant inverse relation was observed between dietary folate equivalent (R(2) = 0.201, B = -0.002, P = .045, 95% confidence interval [CI] [-0.004, -0.001]) and FA (R(2) = 0.255, B = -0.005, P = .036, 95% CI [-0.009, -0.002]) consumption and migraine frequency. It was also observed that in individuals with the CC genotype for the MTHFR C677T variant, migraine frequency was significantly linked to FA consumption (R(2) = 0.106, B = -0.004, P = .029, 95% CI [-0.007, -0.004]). CONCLUSIONS: The results from this study indicate that folate intake in the form of FA may influence migraine frequency in female MA sufferers.


Asunto(s)
Personas con Discapacidad , Ácido Fólico/administración & dosificación , Trastornos Migrañosos/dietoterapia , Trastornos Migrañosos/genética , Complejo Vitamínico B/administración & dosificación , Administración Oral , Adolescente , Adulto , Anciano , Método Doble Ciego , Femenino , Ácido Fólico/metabolismo , Genotipo , Homocisteína/sangre , Humanos , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Persona de Mediana Edad , Mutación/genética , Análisis de Regresión , Complejo Vitamínico B/metabolismo , Adulto Joven
2.
J Agric Food Chem ; 60(38): 9631-41, 2012 Sep 26.
Artículo en Inglés | MEDLINE | ID: mdl-22946519

RESUMEN

This study investigated Nrf2-activating properties of a coffee blend combining raw coffee bean constituents with 5-O-caffeoylquinic acid (CGA) as a lead component with typical roasting products such as N-methylpyridinium (NMP). In cell culture (HT29) the respective coffee extract (CN-CE) increased nuclear Nrf2 translocation and enhanced the transcription of ARE-dependent genes as exemplified for NAD(P)H:quinone oxidoreductase and glutathione-S-transferase (GST)A1, reflected in the protein level by an increase in GST enzyme activity. In a pilot human intervention study (29 healthy volunteers), daily consumption of 750 mL of CN-coffee for 4 weeks increased Nrf2 transcription in peripheral blood lymphocytes on average. However, the transcriptional response pattern of Nrf2/ARE-dependent genes showed substantial interindividual variations. The presence of SNPs in the Nrf2-promoter, reported recently, as well as the detection of GSTT1*0 (null) genotypes in the study collective strengthens the hypothesis that coffee acts as a modulator of Nrf2-dependent gene response in humans, but genetic polymorphisms play an important role in the individual response pattern.


Asunto(s)
Ácido Clorogénico/análogos & derivados , Café/química , Factor 2 Relacionado con NF-E2/genética , Compuestos de Piridinio/farmacología , Ácido Quínico/análogos & derivados , Ácido Clorogénico/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Glutatión Transferasa/genética , Células HT29/efectos de los fármacos , Humanos , Linfocitos/efectos de los fármacos , NAD(P)H Deshidrogenasa (Quinona)/genética , Factor 2 Relacionado con NF-E2/metabolismo , Polimorfismo de Nucleótido Simple , Transporte de Proteínas/efectos de los fármacos , Ácido Quínico/farmacología , Elementos de Respuesta
3.
Pharmacogenet Genomics ; 22(10): 741-9, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22926161

RESUMEN

BACKGROUND: Migraine is a chronic disabling neurovascular condition that may in part be caused by endothelial and cerebrovascular disruption induced by hyperhomocysteinaemia. We have previously provided evidence indicating that reduction of homocysteine by vitamin supplementation can reduce the occurrence of migraine in women. The current study examined the genotypic effects of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene variants on the occurrence of migraine in response to vitamin supplementation. METHODS: This was a 6-month randomized, double-blinded placebo-controlled trial of daily vitamin B supplementation (B(6), B(9) and B(12)) on reduction of homocysteine and of the occurrence of migraine in 206 female patients diagnosed with migraine with aura. RESULTS: Vitamin supplementation significantly reduced homocysteine levels (P<0.001), severity of headache in migraine (P=0.017) and high migraine disability (P=0.022) in migraineurs compared with the placebo effect (P>0.1). When the vitamin-treated group was stratified by genotype, the C allele carriers of the MTHFR C677T variant showed a higher reduction in homocysteine levels (P<0.001), severity of pain in migraine (P=0.01) and percentage of high migraine disability (P=0.009) compared with those with the TT genotypes. Similarly, the A allele carriers of the MTRR A66G variants showed a higher level of reduction in homocysteine levels (P<0.001), severity of pain in migraine (P=0.002) and percentage of high migraine disability (P=0.006) compared with those with the GG genotypes. Genotypic analysis for both genes combined indicated that the treatment effect modification of the MTRR variant was independent of the MTHFR variant. CONCLUSION: This provided further evidence that vitamin supplementation is effective in reducing migraine and also that both MTHFR and MTRR gene variants are acting independently to influence treatment response in female migraineurs.


Asunto(s)
Suplementos Dietéticos , Ferredoxina-NADP Reductasa/genética , Genotipo , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Migraña con Aura/tratamiento farmacológico , Vitaminas/administración & dosificación , Adolescente , Adulto , Alelos , Método Doble Ciego , Femenino , Ácido Fólico/administración & dosificación , Humanos , Persona de Mediana Edad , Migraña con Aura/enzimología , Migraña con Aura/genética , Efecto Placebo , Vitamina B 12/administración & dosificación , Vitamina B 6/administración & dosificación , Adulto Joven
4.
Mol Biol Rep ; 39(6): 7155-62, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22314914

RESUMEN

The Nrf2/ARE pathway is a major cellular defense mechanism that prevents damage by reactive oxygen species through induction of antioxidative phase II enzymes. However, the activity of the Nrf2/ARE system is not uniform with variability in response presumed to be dependent on the Nrf2 genotype. We recently completed a pilot human coffee intervention trial with healthy humans, where large interindividual differences in the antioxidative response to the study coffee were examined. Here, we address the question whether differences in the modulation of Nrf2 gene transcription, assessed as an induction of Nrf2 gene transcription by Q-PCR, might be correlated with specific Nrf2 genotypes. To date, nine single nucleotide polymorphisms (SNPs) have been identified in the Nrf2 (NFE2L2) gene. Two of these, the -617C/A and -651G/A SNPs are located within the promoter region and have previously been reported to influence the activity of the Nrf2/ARE pathway by reducing Nrf2 transcriptional activity. Sequencing of the critical Nrf2 gene promoter region not only confirmed the existence of these SNPs within the participants of the trial at the expected frequency (33% carrying the -617C/A, 17% the -651G/A and 56% the -653A/G SNP) but also indicated reduced Nrf2 gene transcription associated with a normal diet if the SNPs at position -617, -651 or -653 were present. Of note, the data also indicated the study coffee increased Nrf2 gene transcription even in SNP carriers. This further highlights the relevance of genotype-dependent induction of Nrf2 gene transcription that appears to be largely influenced by dietary factors.


Asunto(s)
Café , Factor 2 Relacionado con NF-E2/genética , Transcripción Genética/efectos de los fármacos , Activación Transcripcional/efectos de los fármacos , Antioxidantes/metabolismo , Secuencia de Bases , Cafeína/farmacología , Daño del ADN , Frecuencia de los Genes , Estudios de Asociación Genética , Genotipo , Glutatión/sangre , Humanos , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Masculino , Factor 2 Relacionado con NF-E2/metabolismo , Polimorfismo de Nucleótido Simple , Análisis de Secuencia de ADN
5.
Artículo en Inglés | MEDLINE | ID: mdl-20047890

RESUMEN

Infusions and decoctions of Cymbopogon ambiguus have been used traditionally in Australia for the treatment of headache, chest infections and muscle cramps. The aim of the present study was to screen and identify bioactive compounds from C. ambiguus that could explain this plant's anti-headache activity. A dichloromethane extract of C. ambiguus was identified as having activity in adenosine-diphosphate-induced human platelet aggregation and serotonin-release inhibition bioassays. Subsequent fractionation of this extract led to the isolation of four phenylpropenoids, eugenol, elemicin, eugenol methylether and trans-isoelemicin. While both eugenol and elemicin exhibited dose-dependent inhibition of ADP-induced human platelet serotonin release, only eugenol displayed potent inhibitory activity with an IC50 value of 46.6 µ M, in comparison to aspirin, with an IC50 value of 46.1 µ M. These findings provide evidence to support the therapeutic efficacy of C. ambiguus in the non-conventional treatment of headache and inflammatory conditions.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA